Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 5,992

Document Document Title
WO/2016/108282A1
 A compound represented by general formula (III), and the use of a tautomer or stereoisomer of said compound, or a pharmacologically acceptable salt or solvate thereof, as a treatment for gout or hyperuricemia. (III) (In the formula, R...  
WO/2016/097626A1
The invention relates to novel compounds, to the synthesis method thereof and to the use of same in medicine and in cosmetics. The invention relates to novel compounds, ligands that modulate RAR receptors.  
WO/2016/100897A1
Thiadiazolyl-oximinoacetic acid derivatives have been synthesized, which are useful in the manufacture of cephalosporin antibiotic compounds. Compound (1 ) (TATD) is commercially available (CAS No. 76028-96-1 ). It has now been discovere...  
WO/2016/087257A1
Compounds of formula I wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in...  
WO/2016/083303A1
The present invention provides process for the preparation of polymers comprising at least unit of formula (1), which process comprises the step of (v) treating a compound of formula (5), wherein Y2 is I, Br, CI or O-S(O)2CF3, with an S-...  
WO/2016/077629A1
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological...  
WO/2016/059093A1
The present invention relates to sulfonylurea analogous compounds comprising a sulfonylurea moiety and a photoresponsive moiety. The present invention further relates to methods for generating the sulfonylurea analogous compounds of the ...  
WO/2016/052439A1
 A method for producing 5-amino-3 substituted-1,2,4-thiadiazole, the method having a step for obtaining a compound represented by formula (II) by sequentially adding a brominating agent and a base to a mixture that includes an alcohol,...  
WO/2016/053767A1
The present invention provides four crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pa...  
WO/2016/042435A1
The present invention relates to new thiadiazoles having general formula (I) and their use as herbicides.  
WO/2016/037595A1
The invention relates to substituted l,2,3-thiadiazol-5yl-urea derivatives, their use as anti- senescence and anti-stress factors of plant cells, organs and the whole plant, and preparations containing these derivatives.  
WO/2016/030443A1
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2015/196071A9
The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features method...  
WO/2016/025364A1
The present invention provides a novel synthesis of verubecestat, and two novel crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliora...  
WO/2016/025632A1
The present invention relates to new semiconducting compounds having at least one optionally substituted benzo[d][1,2,3]thiadiazole moiety. The compounds disclosed herein can exhibit high carrier mobility and/or efficient light absorptio...  
WO/2016/015593A1
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...  
WO/2015/196258A1
The present disclosure relates generally, but not exclusively, to compounds and their use as enzyme interacting agents, in particular, agents which interact with one or more enzymes in the sphingolipid biosynthesis pathway. The disclosur...  
WO/2015/199987A1
A compound of Formula (I). In this formula, each of R1, R2, R3, R4, R5, R6, R7, L1, L2, L3, W, X, Y, and Z is defined herein. Also disclosed are a composition containing a compound of Formula (I) and a method for enhancing the sweet tast...  
WO/2015/196071A1
The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features method...  
WO/2015/191630A1
Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.  
WO/2015/143652A8
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, ...  
WO/2015/101957A3
The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or d...  
WO/2015/163817A1
A fluorophore or conjugated polymer with aggregation-induced emission characteristics useful for drug tracking and delivery, identification and labeling of biological subjects, such as cells or parts of a cell, as well as for imaging, an...  
WO/2015/101958A3
The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or d...  
WO/2015/159098A1
There are provided compounds of the formula D-S1-A-S2-B1 wherein A comprises a 2,7- disubstituted 9,9-fluoroalkyl fluorene diradical of the formula wherein S1, S2, D and B1 have meanings given in the description that are useful as charge...  
WO/2015/156417A1
The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases ...  
WO/2015/157382A1
This disclosure relates to asparagine endopeptidase inhibitors and compositions and uses related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are useful for treating or preventing neurodegenerative diseases an...  
WO/2015/150824A1
The invention relates to compounds in the treatment or prevention of disorders associated with Lamin A and/or Lamin C depletion or LMNA mutations, such as laminopathy, premature ageing disorders, normal ageing and cancer(such as a cancer...  
WO/2015/143653A1
The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of...  
WO/2015/143652A1
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula(I) which are tropomyosin-related kinase(Trk)family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, ...  
WO/2015/138869A1
The present disclosure provides new materials that combine the advantages of well-defined polymeric starting materials and the convenience of surface modification by physical methods into one package and, thus, offers a general and power...  
WO/2015/125085A1
The present invention relates to a compound of formula (I), or a tautomer, stereoisomer, geometrical isomer, prodrug, carboxylic acid isostere, solvate, polymorph, N-oxide, S-oxide or pharmaceutically acceptable salt thereof, which are G...  
WO/2015/108136A1
The present invention provides: a novel α-substituted glycinamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the compound or the pharmacologically acceptable salt; and a use of the...  
WO/2015/107541A1
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use ...  
WO/2014/147021A3
The present invention relates to substituted N-(phenyl-heteroaryl) -3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing sai...  
WO/2015/104433A1
The invention relates to benzo[c][1,2,5]oxadiazole derivatives, and the use thereof as antibiotics and in particular for the treatment and/or prevention of diseases caused by bacteria, in particular of diseases caused by Helicobacter.  
WO/2015/101958A2
The present disclosure provides compounds of formula (I) to (III) as glutaminase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or d...  
WO/2015/100441A1
Disclosed are conjugated polymers having desirable properties as semiconducting materials. Such polymers are cheap and easy to synthesize, and can exhibit good solubility and great solution processibility, and that enable highly efficien...  
WO/2015/094930A1
In its many embodiments, the present invention provides certain C-6 spirocarbocyclic iminothiadiazine compounds, including compounds Formula (I): or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and said ta...  
WO/2015/074180A1
Disclosed is a method for preparing thiadiazolylamide compounds. 2-sulfinyl-5-(trifluoromethyl)-1,3,4-thiadiazole (II) and 2-sulfuryl--5- (trifluoromethyl)-1,3,4-thiadiazole (II') are mixed in mass ratio of 99:1-1:99 as mixed raw materia...  
WO/2015/031109A8
Compounds, or pharmaceutically acceptable salts or esters thereof, having a structure of: wherein each of R1-R5 is individually selected from H, halogen, optionally substituted alkyl, optionally substituted alkoxy, nitro, sulfonamide, hy...  
WO/2015/033303A1
The present invention relates to cyclic peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The i...  
WO/2015/033301A1
The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeut...  
WO/2015/033299A1
The present invention relates to 1,2,4-oxadiazole and 1,2,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signaling pathway. The invention also refers to derivatives of the therapeuti...  
WO/2015/031109A1
Compounds, or pharmaceutically acceptable salts or esters thereof, having a structure of: wherein each of R1-R5 is individually selected from H, halogen, optionally substituted alkyl, optionally substituted alkoxy, nitro, sulfonamide, hy...  
WO/2015/016442A1
The present invention relates to a novel phenylthiazole-based hydroxamic acid compound and an anti-cancer composition containing same as an active ingredient. A hydroxamic acid compound according to the present invention exhibits anti-ca...  
WO/2015/006100A1
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2014/153100A3
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity. Methods ...  
WO/2014/181137A1
The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.  
WO/2014/173904A1
The present invention relates to compounds of formula (I) and their uses. In particular, though not exclusively, it concerns heterocyclic compounds that inhibit the biogenesis of adhesive pili in Gram- negative bacteria, and their use in...  

Matches 101 - 150 out of 5,992